You are here
- Home
- Diseases & Conditions
- All Diseases and Conditions
A 30 day international, randomized, parallel-group, double-blind, placebo-controlled phase IV study to evaluate efficacy and safety of pre-hospital vs. in-hospital initiation of ticagrelor therapy in STEMI patients planned for PCI
- Disease
- myocardial infarction
- Drug Name
- Brilinta
- Generic Name
- Ticagrelor
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Sep 12, 2011
- Study Name
- D5130L00006
- Study Id
- D5130L00006
- ClinicalTrials.gov ID
- NCT01347580
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
